

Table 1. Conditions used for determination of receptor affinity.

Receptor	Radioligand	Tissue	Unspecific bond	Incubation conditions		
				Medium	Temperature	Time
5-HT <sub>1A</sub>	[ <sup>3</sup> H]-8-OH-DPAT	Rat cerebral cortex	5-HT 10 $\mu$ M	1	37°C	15 min
5-HT <sub>2A</sub>	[ <sup>3</sup> H]Ketanserin	Rat cerebral cortex	Cinanserin 1 $\mu$ M	2	37°C	15 min
5-HT <sub>3</sub>	[ <sup>3</sup> H]LY 278584	Rat cerebral cortex	5-HT 10 $\mu$ M	3	25°C	30 min
5-HT <sub>4</sub>	[ <sup>3</sup> H]GR 113808	Rat striatum	5-HT 30 $\mu$ M	4	37°C	30 min
5-HT <sub>7</sub>	[ <sup>3</sup> H]-5-CT	Rat hypothalamus	5-HT 10 $\mu$ M	5	23°C	120 min
$\alpha_1$	[ <sup>3</sup> H]prazosin	Rat cerebral cortex	Phentolamine 10 $\mu$ M	6	25°C	30 min
D <sub>2</sub>	[ <sup>3</sup> H]spiperone	Rat striatum	( $\pm$ )Butaclamol 1 $\mu$ M	7	37°C	15 min

Incubation medium:

1. MgSO<sub>4</sub> 5 mM and EDTA 0.5 mM in Tris-HCl 50 mM, pH 7.4
2. MgSO<sub>4</sub> 10 mM, EDTA 0.5 mM, ascorbic acid 0.1% and pargiline 10  $\mu$ M in Tris-HCl 50 mM, pH 7.4
3. Pargiline 10  $\mu$ M, ascorbic acid 0.6 mM and CaCl<sub>2</sub> 5 mM in Tris-HCl 50 mM, pH 7.4
4. HEPES 50 mM, pH 7.4
5. CaCl<sub>2</sub> 4 mM, ascorbic acid 1 mg/mL, pargiline 0.01 mM and (-)pindolol 3  $\mu$ M in Tris-HCl 50 mM, pH 7.4
6. MgCl<sub>2</sub> 2.5 mM in Tris-HCl 50 mM, pH 7.4
7. NaCl 120 mM, KCl 5 mM, CaCl<sub>2</sub> 1 mM and ascorbic acid 5.7 mM in Tris-HCl 50 mM, pH 7.4

Table 2. Receptor affinity data obtained.

Compound	$K_i \pm \text{E.E. (nM)}$					
	5-HT <sub>1A</sub>	5-HT <sub>2A</sub>	5-HT <sub>3</sub>	5-HT <sub>4</sub>	5-HT <sub>7</sub>	$\alpha_1$
1	1.23 $\pm$ 0.09	>10000	>10000	>10000	299.3 $\pm$ 7.7	121.1 $\pm$ 1.8
2	19.9 $\pm$ 6.0	>1000	>10000	>10000	492.7 $\pm$ 1.5	50.0 $\pm$ 6.2
3	13.2 $\pm$ 1.0	>1000	>10000	>10000	>1000	8.5 $\pm$ 0.6
4	30.1 $\pm$ 0.6	>1000	>10000	>10000	168.8 $\pm$ 18.1	> 1000
5	5.5 $\pm$ 0.4	>1000	>10000	>10000	123.0 $\pm$ 17.8	27.7 $\pm$ 4.0
6	1.3 $\pm$ 0.2	>1000	>10000	>10000	87.0 $\pm$ 3.1	26.3 $\pm$ 2.4
7	>1000	>1000	NA	>10000	>10000	49.6 $\pm$ 2.9
8	51.01 $\pm$ 0.47	>1000	>10000	NA	8.04 $\pm$ 0.87	>10000
9	27.9 $\pm$ 3.1	>10000	>1000	>10000	>1000	> 1000
10	15.0 $\pm$ 1.0	>1000	>1000	>1000	>10000	> 1000
11	43.2 $\pm$ 4.5	157.3 $\pm$ 0.65	>10000	594.3 $\pm$ 43.7	74.05 $\pm$ 7.3	99.05 $\pm$ 14
12	25.5 $\pm$ 0.9	>10000	>1000	>10000	>1000	> 1000
13	9.8 $\pm$ 0.7	>10000	>10000	>1000	55.0 $\pm$ 0.3	26.9 $\pm$ 4.5
14	2.4 $\pm$ 0.6	41.5 $\pm$ 7.5	>1000	>10000	42.6 $\pm$ 4.4	30.9 $\pm$ 4.9
15	4.5 $\pm$ 0.2	38.5 $\pm$ 7.7	>10000	NA	19.9 $\pm$ 0.8	54.7 $\pm$ 1.8
16	>10000	>10000	>1000	>10000	>10000	>1000
17	>10000	NA	NA	NA	NA	NA
18	868.5 $\pm$ 23.1	>10000	NA	>10000	NA	>10000
19	73.9 $\pm$ 5.0	>1000	>10000	>10000	>10000	>10000
20	137.6 $\pm$ 26.3	>10000	>1000	>10000	>10000	>10000
21	>1000	>10000	>10000	>1000	>10000	>10000
5-HT	0.84 $\pm$ 0.27	5.9 $\pm$ 0.2	13.8 $\pm$ 2.4	53.8 $\pm$ 3.3	4.2 $\pm$ 0.5	-
8-OH-DPAT	1.0 $\pm$ 0.1	-	-	-	83.8	-
Cinanserin	-	2.6 $\pm$ 0.4	-	-	-	-
Onansetron	-	-	0.77 $\pm$ 0.01	-	-	-
RS-39604	-	-	-	3.9 $\pm$ 0.2	-	-
5-CT	-	-	-	-	1.8 $\pm$ 0.6	-
Phentolamine	-	-	-	-	-	6.1 $\pm$ 0.1
Butaclamol	-	-	-	-	-	49.0 $\pm$ 5.8